Known variants of CD20-negative DLBCL include plasmablastic lymphoma, primary effusion lymphoma, large B-cell lymphoma arising in human herpesvirus 8-associated multicentric Castleman disease and anaplastic lymphoma kinase-positive DLBCL.

Dec 2, 2016 · Introduction: CD20-negative subtypes of diffuse large B-cell lymphoma (DLBCL) are rare, aggressive malignancies. Recently, cancer registries in the United States (US) have distinguished specific subtypes of CD20-negative DLBCL: since 2004-primary effusion lymphoma (PEL), and since 2010-plasmablastic lymphoma (PBL), ALK+ large B-cell lymphoma ...

Nov 19, 2010 · The survival outcome was poor compared with CD20-positive DLBLC because of high relapse rate. It was caused without rituximab treatment in CD20-negative. Development of novel target agents like rituximab should be explored to improve outcome and maintain the CR status of CD20-negative DLBCL.

CD19 and CD20 are B cell–specific antigens whose expression is heterogeneous when analyzed by flow cytometry (FCM). We determined the association between CD20 expression and clinical outcome in patients with diffuse large B-cell lymphoma (DLBCL). ...

Mar 26, 2025 · CD20 can be used to tell the difference between these two cancers in that test results for CD20 would usually be positive in the case of DLBCL but negative for ALCL. How Is It Tested? A special technique called immunohistochemistry (IHC) is used to identify CD20 and determine whether an abnormal cancerous white blood cell (lymphocyte in ...

Feb 7, 2017 · CD20 negative B cell non-Hodgkin lymphoma (NHL) is rare and accounts for approximately 1-2% of B cell lymphomas. CD20- negative NHL is frequently associated with extranodal involvement, atypical morphology, aggressive clinical behaviour, resistance to standard chemotherapy and poor prognosis.

Dec 2, 2016 · Introduction: CD20-negative subtypes of diffuse large B-cell lymphoma (DLBCL) are rare, aggressive malignancies. Recently, cancer registries in the United States (US) have distinguished specific subtypes of CD20-negative DLBCL: since 2004-primary effusion lymphoma (PEL), and since 2010-plasmablastic lymphoma (PBL), ALK+ large B-cell lymphoma ...

4 days ago · The objective of this study is to evaluate the clinical presentations, treatment strategies, and prognostic factors for prostate diffuse large B-cell lymphoma (DLBCL), aiming to improve patient ...

Feb 2, 2025 · Negative selective pressure following anti-CD19 and CD20 therapy can reduce the efficacy of subsequent therapies. The current standard of care does not require retesting of IHC or flow prior to third line therapy. 64% of patients who …

CD20 expression is absent in a variety of diffuse large B cell lymphomas (DLBCLs), including plasmablastic lymphoma, primary effusion lymphoma, anaplastic lymphoma, kinase-positive DLBCL, and large B cell lymphoma arising in human herpesvirus 8-associated multicentric Castleman disease.